The Cost of Preserving the Status Quo – It’s Not an All or Nothing Decision Anymore

Whether you’re a laboratory, pathology practice, molecular diagnostic provider, remote patient monitoring organization, or one of the nation’s largest hospitals offering ancillary services, factors causing revenue compression are threatening your bottom line. They include: Testing volume and reimbursement related to COVID-19. With volume initially dropping as much as 60% during the pandemic...

Read


Automation of Prior Authorizations and Appeals is Possible and Key to Reducing Costs

Many issues are challenging diagnostic providers’ ability to maximize payor reimbursements, such as the significant increase in required prior authorizations (PAs) and the high cost of appeals.These issues are even more difficult for laboratories and remote patient monitoring device companies using traditional billing systems that have few or no automation tools. Hospital outreach programs and...

Read


Digital Pathology Goes Mainstream

Enjoy the following content from our partner, Proscia. COVID-19 has disrupted laboratory medicine in many ways, causing a strong need for new testing, social distancing, and telemedicine.The pandemic has been especially challenging for pathology, which has remained mostly unchanged over the last 150 years. The field has held onto its traditional practices centering around a pathologist reading...

Read


UHC Suspends Prior Auth Requirements for Trichomonas & Candida, Will Adopt CMS Billing Policy for Prostates on January 1, 2021

Suspension of Trichomonas and Candida Prior Auth Requirements Beginning Oct. 1, 2020, for all commercial and UnitedHealthcare Community Plan plans included in the genetic and molecular testing program, UHC will be suspending prior authorization and notification requirements for the following three genetic and molecular CPT codes performed in an outpatient setting: 87480: Infectious agent...

Read


XIFIN RPM 12: Additional Appeals Automation Capabilities, Expanded Advanced Analytics and Patient Data Discovery, and More

Laboratory testing volume is at an all-time high. Molecular testing volume, for example, is currently at 275% of pre-COVID-19 levels. Diagnostic providers must transform their revenue cycle management (RCM) to adapt quickly to this changed world. This is not a challenge that can be overcome by throwing people at it. That is not a sustainable, scalable solution and during the COVID-19 pandemic is...

Read


3 Ways COVID-19 Will Impact Q4 Testing

As COVID continues to challenge the laboratory industry, XIFIN executives expect a 15% increase in COVID-19 volumes in the fall and regional labs to pick up overflow from larger, national players.This news was announced at a recent conference called “COVID-19’s Impact on Lab Industry Testing Volumes and Dynamics – September Update,” where XIFIN CEO Lâle White, XIFIN Executive Vice President...

Read


Streamlining Diagnostic Processes: How Dolbey Fusion Narrate Integrates with XIFIN LIS

Enjoy the following content from our partner, Dolbey. Thousands – or even millions – of data points can be recorded in and referenced from an LIS, but moving back and forth between the LIS and lab tests can drag down your productivity. With speech recognition, you can reference and record information in an LIS without a mouse and keyboard. One of the most powerful laboratory information...

Read


XIFIN Launches XIFIN LIS 7 and Announces a New Strategic Partnership with Dolbey

The COVID-19 pandemic has created a tremendous uptick in diagnostic testing. The significant drop in routine test volume experienced in late March through April that was due to the COVID-19 pandemic has for the most part recovered, and the addition of COVID testing has pushed clinical laboratory test volumes well above traditional levels. This means lab leaders need new capabilities and...

Read